- Home
- BINI vs OGEN Comparison
BINI vs OGEN Comparison
Compare BINI & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BINI
- OGEN
- Stock Information
- Founded
- BINI N/A
- OGEN 1996
- Country
- BINI United States
- OGEN United States
- Employees
- BINI N/A
- OGEN N/A
- Industry
- BINI
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- BINI
- OGEN Health Care
- Exchange
- BINI Nasdaq
- OGEN Nasdaq
- Market Cap
- BINI 1.2M
- OGEN 1.2M
- IPO Year
- BINI N/A
- OGEN N/A
- Fundamental
- Price
- BINI $0.18
- OGEN $1.06
- Analyst Decision
- BINI
- OGEN
- Analyst Count
- BINI 0
- OGEN 0
- Target Price
- BINI N/A
- OGEN N/A
- AVG Volume (30 Days)
- BINI 26.8M
- OGEN 112.5K
- Earning Date
- BINI 08-14-2025
- OGEN 08-08-2025
- Dividend Yield
- BINI N/A
- OGEN N/A
- EPS Growth
- BINI N/A
- OGEN N/A
- EPS
- BINI N/A
- OGEN N/A
- Revenue
- BINI $9,340,063.00
- OGEN N/A
- Revenue This Year
- BINI N/A
- OGEN N/A
- Revenue Next Year
- BINI N/A
- OGEN N/A
- P/E Ratio
- BINI N/A
- OGEN N/A
- Revenue Growth
- BINI 5865.42
- OGEN N/A
- 52 Week Low
- BINI $0.18
- OGEN $1.01
- 52 Week High
- BINI $3,810,000,000.00
- OGEN $36.90
- Technical
- Relative Strength Index (RSI)
- BINI N/A
- OGEN 32.50
- Support Level
- BINI N/A
- OGEN $1.01
- Resistance Level
- BINI N/A
- OGEN $1.13
- Average True Range (ATR)
- BINI 0.00
- OGEN 0.05
- MACD
- BINI 0.00
- OGEN 0.04
- Stochastic Oscillator
- BINI 0.00
- OGEN 26.32
About BINI Bollinger Innovations Inc.
Bollinger Innovations Inc is a Southern California-based automotive company building the next generation of commercial electric vehicles (EVs) with U.S. based vehicle manufacturing located in Tunica, Mississippi. both the ONE, a Class 1 EV cargo van, and THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (CARB) and EPA certified and available for sale in the U.S.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.